← All organizations
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2010First marketed drug
Sep 12, 2019First NDA
Sep 12, 2019Last known activity
Feb 1, 2025
Timeline
Drugs by trial phase (7 distinct, 31 trials)
Phase 1 (3 own, 0 via acquisition)
Indications
Marketed drugs (1)
Recent trials (49)
- NCT06810167CollaboratorPhase 3Feb 1, 2025
- NCT06460038CollaboratorPhase 2Dec 31, 2024
- NCT06553547Lead sponsorPhase 2Jul 24, 2024
- NCT06553547OfficialPhase 2Jul 24, 2024
- NCT05995899CollaboratorPhase 4Dec 31, 2023
- NCT06203444OfficialPhase 1Nov 27, 2023
- NCT06203444Lead sponsorPhase 1Nov 27, 2023
- NCT05905926Study chairPhase 3Feb 17, 2023
- NCT05905926Lead sponsorPhase 3Feb 17, 2023
- NCT05643534Study chairPhase 3Nov 15, 2022
- NCT05643534Lead sponsorPhase 3Nov 15, 2022
- NCT04780841Lead sponsorPhase 2Jan 11, 2021
- NCT04549597Lead sponsorPhase 4Nov 6, 2020
- NCT03988920Lead sponsorPhase 4Jun 30, 2019
- NCT03824587Study chairPhase 2/Phase 3Feb 28, 2019
Details
- Founded
- Fremont, CA, US Jun 1, 2007
- First NDA
- Sep 12, 2019
- Last known activity
- Feb 1, 2025